Using hyperspectral imaging to assess endothelial dysfunction in preeclampsia
Systematic Evaluation of Endothelial Dysfunction as a Prognostic Marker for Outcomes in Women With Preeclampsia
This study is testing if a special imaging technique can help doctors see how blood vessel function changes in pregnant women with preeclampsia to better understand the risks for both mom and baby.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 385 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Heidelberg University Academic / other |
| Locations | 1 site (Heidelberg) |
| Trial ID | NCT06912477 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the use of hyperspectral imaging as a diagnostic and prognostic tool for preeclampsia, a pregnancy-related hypertensive disorder. It aims to evaluate the changes in endothelial and vascular function associated with preeclampsia, which can lead to severe complications for both mother and fetus. The study will involve women with singleton pregnancies who are at least 18 years old and able to provide informed consent. By utilizing non-invasive hyperspectral imaging, the researchers hope to identify microcirculatory disturbances that may persist postpartum and contribute to long-term cardiovascular risks.
Who should consider this trial
Good fit: Ideal candidates for this study are women with singleton pregnancies who are 18 years or older and can provide informed consent.
Not a fit: Patients with severe fetal anomalies or those unable to provide consent, including those with language barriers or certain skin types, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new non-invasive method for early diagnosis and risk assessment of cardiovascular complications in women with a history of preeclampsia.
How similar studies have performed: While hyperspectral imaging has not been previously studied in the context of preeclampsia, its application in other medical fields has shown promise, suggesting potential for success in this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * singleton pregnancies * Age ≥ 18 years * Patient's ability to provide consent * written informed consent Exclusion Criteria: * Lack of consent * Language barrier * Dark to very dark skin type * Severe fetal chromosomal/genetic/structural anomalies * Laboratory changes in LDH, creatinine, or platelets due to other causes (e.g., isolated thrombocytopenia, e.g., immune thrombocytopenia, carcinoma)
Where this trial is running
Heidelberg
- Heidelberg University Hospital, Department of Gynecology and Obstetrics — Heidelberg, Germany (Recruiting)
Study contacts
- Principal investigator: Dr. med. Alexandra von Au — University Heidelberg
- Study coordinator: Dr. med. Anna Scholz
- Email: anna.scholz@med.uni-heidelberg.de
- Phone: +49 6221 56 32080
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.